Invivyd Inc (IVVD)
1.84
+0.03
(+1.66%)
USD |
NASDAQ |
May 31, 16:00
1.83
-0.01
(-0.54%)
After-Hours: 20:00
Invivyd Enterprise Value: 30.15M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 30.15M |
| May 30, 2024 | 26.57M |
| May 29, 2024 | 11.06M |
| May 28, 2024 | 20.61M |
| May 24, 2024 | 40.89M |
| May 23, 2024 | 50.44M |
| May 22, 2024 | 68.33M |
| May 21, 2024 | 74.30M |
| May 20, 2024 | 79.07M |
| May 17, 2024 | 96.97M |
| May 16, 2024 | 102.94M |
| May 15, 2024 | 104.13M |
| May 14, 2024 | 100.55M |
| May 13, 2024 | 93.39M |
| May 10, 2024 | 80.27M |
| May 09, 2024 | 99.36M |
| May 08, 2024 | 112.48M |
| May 07, 2024 | 110.09M |
| May 06, 2024 | 92.20M |
| May 03, 2024 | 99.36M |
| May 02, 2024 | 93.39M |
| May 01, 2024 | 99.13M |
| April 30, 2024 | 75.28M |
| April 29, 2024 | 58.59M |
| April 26, 2024 | 66.94M |
| Date | Value |
|---|---|
| April 25, 2024 | 57.40M |
| April 24, 2024 | 64.55M |
| April 23, 2024 | 81.24M |
| April 22, 2024 | 71.71M |
| April 19, 2024 | 84.82M |
| April 18, 2024 | 90.78M |
| April 17, 2024 | 106.28M |
| April 16, 2024 | 132.51M |
| April 15, 2024 | 145.62M |
| April 12, 2024 | 162.31M |
| April 11, 2024 | 174.83M |
| April 10, 2024 | 169.47M |
| April 09, 2024 | 170.66M |
| April 08, 2024 | 175.43M |
| April 05, 2024 | 204.04M |
| April 04, 2024 | 237.42M |
| April 03, 2024 | 279.15M |
| April 02, 2024 | 264.84M |
| April 01, 2024 | 317.30M |
| March 28, 2024 | 328.70M |
| March 27, 2024 | 276.24M |
| March 26, 2024 | 235.71M |
| March 25, 2024 | 184.44M |
| March 22, 2024 | 319.16M |
| March 21, 2024 | 167.75M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-259.55M
Minimum
Dec 28 2022
5.846B
Maximum
Sep 16 2021
365.80M
Average
-73.28M
Median
Dec 04 2023
Enterprise Value Benchmarks
| Vanda Pharmaceuticals Inc | -95.58M |
| Viking Therapeutics Inc | 5.907B |
| Stoke Therapeutics Inc | 582.89M |
| 180 Life Sciences Corp | 1.638M |
| MAIA Biotechnology Inc | 95.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.50M |
| Total Expenses (Quarterly) | 46.09M |
| EPS Diluted (Quarterly) | -0.38 |
| Earnings Yield | -101.6% |